文献速递白内障与屈光手术角膜与眼表疾病

飞秒激光弧形角膜切开术与环曲面人工晶状体植入术在白内障手术中的随机临床试验

Femtosecond Laser Arcuate Keratotomy vs Toric Intraocular Lens Implantation in Cataract Surgery: A Randomized Clinical Trial.
PubMed 文献 · JAMA Ophthalmol · 2025-01-01

这项随机临床试验于2021年10月至2023年9月在中国浙江大学医学院附属第二医院眼科中心开展,将196例轻中度规则角膜散光(0.75 D至3.00 D)患者按1:1随机分配至飞秒激光弧形角膜切开术(FSAK)组或环曲面人工晶状体(TIOL)植入组。术后3个月两组主观显然验光散光无差异(0.64 D vs 0.54 D,P=.21)。亚组分析显示,散光超过1.5 D或逆规散光时TIOL残留散光更低。

要点

  • 术后3个月FSAK组与TIOL组残余散光无差异(0.64 D vs 0.54 D,P=.21)。
  • 两组裸眼远视力无差异(0.15 logMAR vs 0.14 logMAR,P=.71)。
  • 散光超过1.5 D或逆规散光时,TIOL组残留散光低于FSAK组。

核心结论

  • 在轻中度散光患者中接受飞秒激光辅助白内障手术时,FSAK在散光矫正方面不优于TIOL植入。
  • 对于散光超过1.5 D或逆规散光,TIOL植入的疗效优于FSAK。
  • 作者认为需要未来试验来确定亚组分析所提示的TIOL植入是否比FSAK更有效。

研究设计与样本

  • 随机临床试验,于2021年10月至2023年9月在中国浙江大学医学院附属第二医院眼科中心开展。
  • 共196例患者(平均[SD]年龄68.4[13.7]岁;女性124例[63%])按1:1随机分配至FSAK组(98例[50%])或TIOL组(98例[50%])。
  • FSAK组92例(94%)、TIOL组95例(97%)完成3个月随访。
  • 纳入标准为轻中度规则角膜散光,范围0.75 D至3.00 D。
  • 主要结局为术后3个月主观显然验光。

主要发现

  • 术后3个月两组散光无差异(FSAK组平均[SD] 0.64[0.64] D vs TIOL组0.54[0.55] D;差值0.11 D;95%CI -0.06至0.27 D;P=.21)。
  • FSAK组平均(SD)裸眼远视力为0.15(0.20)logMAR(Snellen等效20/28),TIOL组为0.14(0.19)logMAR(Snellen等效20/28);差值0.01 D;95%CI -0.04至0.06 D;P=.71。
  • 亚组分析显示,治疗散光超过1.5 D或逆规散光时,TIOL植入相比FSAK获得更低的残留散光。

关键数值与推荐

  • 本研究未制定或引用推荐条款。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出需要未来试验来确定亚组分析所提示的TIOL植入是否比FSAK更有效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: After cataract surgery, postoperative residual astigmatism can influence a patient's visual quality and satisfaction. Finding ways to minimize this astigmatism is important. OBJECTIVE: To compare the clinical outcomes of femtosecond laser arcuate keratotomy (FSAK) and toric intraocular lens (TIOL) implantation for astigmatism correction in patients undergoing femtosecond laser-assisted cataract surgery. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial was conducted between October 2021 and September 2023 at the Eye Center of the Second Affiliated Hospital, School of Medicine, Zhejiang University, China. Patients with mild to moderate regular corneal astigmatism ranging from 0.75 diopters (D) to 3.00 D were recruited. INTERVENTIONS: Patients were randomly assigned in a 1:1 ratio to receive FSAK or TIOL implantation. MAIN OUTCOMES AND MEASURES: The primary outcome was the subjective manifest refraction assessed at 3 months postoperatively. RESULTS: A total of 196 patients (mean [SD] age, 68.4 [13.7] years; 124 female [63%]) were randomized to the FSAK group (98 [50%]) or TIOL group (98 [50%]), and 92 patients (94%) and 95 patients (97%), respectively, finished the 3-month follow-up. At 3 months postoperatively, there was no difference in the refractive astigmatism between the 2 groups (mean [SD], 0.64 [0.64] D vs 0.54 [0.55] D; difference, 0.11 D; 95% CI, -0.06 to 0.27 D; P = .21). The mean (SD) uncorrected distance visual acuity was 0.15 (0.20) logMAR (Snellen equivalent, 20/28) for the FSAK group and 0.14 (0.19) logMAR (Snellen equivalent, 20/28) for the TIOL group (difference, 0.01 D; 95% CI, -0.04 to 0.06 D; P = .71). Subgroup analyses showed that TIOL implantation achieved lower residual astigmatism compared with FSAK when treating astigmatism exceeding 1.5 D or against-the-rule astigmatism. CONCLUSIONS AND RELEVANCE: Results of this randomized clinical trial demonstrate that in study participants with mild to moderate astigmatism undergoing femtosecond laser-assisted cataract surgery, FSAK was not superior to TIOL implantation for astigmatism correction. However, for astigmatism exceeding 1.5 D or against-the-rule astigmatism, TIOL implantation demonstrated greater efficacy over FSAK. Future trials are needed to determine if there is greater efficacy of TIOL implantation over FSAK as suggested by subgroup analyses. TRIAL REGISTRATION: ChiCTR.org.cn Identifier: ChiCTR2100051066.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Zhong Y, Chen S, Wang H, et al. Femtosecond Laser Arcuate Keratotomy vs Toric Intraocular Lens Implantation in Cataract Surgery: A Randomized Clinical Trial. JAMA Ophthalmol. 2025. PMID: 39847362. doi:10.1001/jamaophthalmol.2024.5887

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。